Hormonal
Exogenous testosterone therapy increases the risk of cardiovascular-related events in men, with an overall odds ratio of 1.54 compared to placebo.
If you are considering testosterone therapy, be aware that it may increase your risk of cardiovascular events. The overall risk is about 1.5 times higher than placebo. This risk appears higher in trials not funded by pharmaceutical companies. Discuss this risk with your doctor, especially if you have existing heart conditions or are older.
Testosterone therapy increased the risk of a cardiovascular-related event (odds ratio (OR) 1.54, 95% confidence interval (CI) 1.09 to 2.18).
Why this rating
Meta-analysis of 27 RCTs with 2,994 participants provides high-quality evidence, though heterogeneity in event reporting exists.
Source
Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials
Lin Xu et al. · BMC Medicine · 2013
DOI 10.1186/1741-7015-11-108
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →